Stay updated with breaking news from Underlying Comorbidities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New data presented at ACG 2023 showed an approximate 60% success rate of recurrent C difficile prevention in adults with comorbid conditions including CKD and cardiac disease.
Subgroup analysis of Phase 3 trial (PUNCH CD3) looked at health-related quality of life data in patients treated with RBX2660 versus placebo Separate subgroup analysis reviewed efficacy and
New subgroup analyses presented at Digestive Disease Week (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660. Data adds to the growing body
Is the lead author of the edinburgh university study. he explained the findings. in essence, we've got three core findings here. and we've been in the fortunate position of really being able to track the entire scottish population. so, the first is that we've seen 0micron just run through scotland incredibly rapidly. the first case was towards the end of november, november the 23rd, and then in the three to four weeks subsequently, we've seen that it's become the dominant variant in scotland. so, it's basically swept through the population very rapidly. the second issue and a big unanswered qu...
So, in essence, we've got three core findings here. and we've been in the fortunate position of really being able to track the entire scottish population. so, the first is that we've seen 0micron just run through scotland incredibly rapidly. the first case was towards the end of november, november the 23rd, and then in the three to four weeks subsequently, we've seen that it's become the dominant variant in scotland. so, it's basically swept through the population very rapidly. the second issue and a big unanswered question that we've been grappling with is what's the risk of severe outcomes? ...